{"id":10532,"date":"2026-02-17T23:02:33","date_gmt":"2026-02-17T23:02:33","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2026\/02\/17\/biotech-news-compass-psilocybin-data-for-fda\/"},"modified":"2026-02-17T23:02:33","modified_gmt":"2026-02-17T23:02:33","slug":"biotech-news-compass-psilocybin-data-for-fda","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2026\/02\/17\/biotech-news-compass-psilocybin-data-for-fda\/","title":{"rendered":"STAT+: Psilocybin data could be good enough for approval"},"content":{"rendered":"<p>    STAT+: Psilocybin data could be good enough for approval<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p><em>Want to stay on top of the science and politics driving biotech today?\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/readout\/\">Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/em><\/p>\n<p>Good day! Today: A look at growing GLP-1 competition in China, a drug reviewed as part of the FDA\u2019s shiny new fast-track voucher\u00a0hits a roadblock, and Secretary Kennedy\u2019s vaccine overhaul gets a hard look in federal court.<\/p>\n<p>Also, psilocybin may be headed for approval despite mildly anticlimactic remission rates, and Ocular\u2019s wet AMD drug does .\u2026 fine.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2026\/02\/17\/biotech-news-compass-psilocybin-data-for-fda\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Meghana Keshavan<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2026\/02\/17\/biotech-news-compass-psilocybin-data-for-fda\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Psilocybin data could be good enough for approval Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter in your inbox. Good day! Today: A look at growing GLP-1 competition in China, a drug reviewed as part of the FDA\u2019s shiny new fast-track voucher\u00a0hits a roadblock, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,58,2208,2209,2176,858,2207],"tags":[2150],"class_list":["post-10532","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-business","category-drug-development","category-drug-prices","category-pharma","category-research","category-the-readout","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/10532"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=10532"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/10532\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=10532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=10532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=10532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}